HLA
ESPR

Hamilton Lane Advisors’s Esperion Therapeutics ESPR Stock Holding History

Hamilton Lane Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,861
Closed -$251K – 86
2021
Q2 		$251K Sell
11,861
-9,392
-44% -$226K 0.08% 70
2021
Q1 		$596K Sell
21,253
-24,928
-54% -$735K 0.19% 54
2020
Q4 		$1.2M Hold
46,181
– – 0.45% 31
2020
Q3 		$1.72M Hold
46,181
– – 0.83% 22
2020
Q2 		$2.37M Hold
46,181
– – 1.27% 16
2020
Q1 		$1.46M Sell
46,181
-6,645
-13% -$351K 0.84% 21
2019
Q4 		$3.15M Hold
52,826
– – 1.38% 17
2019
Q3 		$1.94M Hold
52,826
– – 0.81% 23
2019
Q2 		$2.46M Hold
52,826
– – 1.22% 15
2019
Q1 		$2.12M Buy
52,826
+31,264
+145% +$1.4M 1.12% 20
2018
Q4 		$992K Hold
21,562
– – 0.87% 24
2018
Q3 		$1M Hold
21,562
– – 0.41% 30
2018
Q2 		$1M Sell
21,562
-10,000
-32% -$505K 0.91% 27
2018
Q1 		$2M Sell
31,562
-83,782
-73% -$6.15M 1.59% 18
2017
Q4 		$7.59M Buy
+115,344
New +$6.21M 3.92% 6
2015
Q3 		– Sell
-23,847
Closed -$1.95M – 53
2015
Q2 		$1.95M Buy
23,847
+19,091
+401% +$1.87M 0.74% 28
2015
Q1 		$440K Buy
+4,756
New +$307K 0.2% 39

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hamilton Lane Advisors's ESPR Position: Q3 2021 in Review

Hamilton Lane Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 11,861 shares — an estimated $251K sold.

Hamilton Lane Advisors first reported a position in ESPR in Q1 2015 and held it in 17 quarters. The position peaked at $7.59M in Q4 2017. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • Hamilton Lane Advisors reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 11,861 Esperion Therapeutics shares in Q3 2021, an estimated $251K.
  • Hamilton Lane Advisors first reported a position in Esperion Therapeutics in Q1 2015 and held it in 17 quarters.
  • Hamilton Lane Advisors's Esperion Therapeutics position peaked at $7.59M in Q4 2017.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Hamilton Lane Advisors's 13F filing for Q3 2021, filed 14 Oct 2021.